# Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

> **NCT06911255** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yoon Jun Kim** · enrollment: 24 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tremelimumab Plus Durvalumab (MEDI4736)
- **PROCEDURE:** Transarterial chemoembolization (TACE)

## Key facts

- **NCT ID:** NCT06911255
- **Lead sponsor:** Yoon Jun Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911255, "Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06911255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*